Interní Med. 2014; 16(5): 196-198

Pneumonic form of the lung cancer

MUDr.Jana Kulísková, prof.MUDr.Vítězslav Kolek, DrSc.
Klinika plicních nemocí a tuberkulózy FN a LF UP Olomouc

Adenocarcinoma with prominent lepidic spread presents, in addition to it´s specific morphology, with certain clinical characteristics as higher

incidence in women, non-smokers and younger patiens and lower susceptibility to conventional cytostatik therapy in comparison to other

subtypes of non-small cell lung carcinoma (NSCLC). About 10 % of NSCLC express receptor for epidermal growth faktor (EGFR), which is predictor

of effectiveness to biologic therapy. We present a case of a 33 years old man, who was treated at the begining for left lung pneumonia. Just with

the passage of 3 months, after antibiotic therapy and repeated radiology controls, the patient was sent to our workplace for further investigation

for persistent infiltration of the left lung. Biopsy established mucinous adenocarcinoma with prominent lepidic spread, already with presence

of metastasis in right lung. Despite the chemotherapy disease progresses and the patient is dying less than a year from the diagnosis. This case

illustrates, that it´s important to think of lung carcinoma also in young age and carry out careful diagnostic of all unsolved radiologic findings.

Keywords: lung carcinoma, lepidic adenocarcinoma, pneumonic form, EGF receptor

Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kulísková J, Kolek V. Pneumonic form of the lung cancer. Interní Med. 2014;16(5):196-198.
Download citation

References

  1. Gandara DR, West H, Chansky K, et al. Bronchioloalveolar carcinoma: a model for investigating the bio logy of epidermal growth factor receptor inhibition. Clin Cancer Res 2004; 10(12 Pt 2): 4205s-4209s. Go to original source... Go to PubMed...
  2. Yano S, Kanematsu T, Miki T, et al. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa). Cancer Sci 2003; 94(5): 453-458. Go to original source... Go to PubMed...
  3. Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008; 3(3): 303-310. Go to original source... Go to PubMed...
  4. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008; 26(9): 1472-1478. Go to original source... Go to PubMed...
  5. Travis WD. World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, Oxford: IARC Press, Oxford University Press 2004.
  6. Henrikson RC, Kaye GI, Mazurkiewicz JE. Respiratory system. In: NMS Histology. 1st ed. Baltimore: Williams and Wilkins 1997: 311-321.
  7. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002; 74(5): 1640-1646. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.